Treatments and outcomes of 97 iTTP patient episodes
| Parameters . | Values . |
|---|---|
| Number (%) who received TPE | 97 (100) |
| Number (%) who received rituximab before recurrence | 38 (39.2) |
| Days to platelet normalization, median (IQR) | 5 (4-7) |
| Number of TPE to achieve clinical response, median (IQR) | 4 (3-5.5) |
| Outcome, n (%) | |
| Remission | 42 (43.3) |
| Recurrence | 55 (56.7) |
| Exacerbation | 39 (40.2) |
| Relapse | 22 (22.7) |
| Relapse after exacerbation | 6 (6.2) |
| Parameters . | Values . |
|---|---|
| Number (%) who received TPE | 97 (100) |
| Number (%) who received rituximab before recurrence | 38 (39.2) |
| Days to platelet normalization, median (IQR) | 5 (4-7) |
| Number of TPE to achieve clinical response, median (IQR) | 4 (3-5.5) |
| Outcome, n (%) | |
| Remission | 42 (43.3) |
| Recurrence | 55 (56.7) |
| Exacerbation | 39 (40.2) |
| Relapse | 22 (22.7) |
| Relapse after exacerbation | 6 (6.2) |